Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi
August 15, 2024 02:58 ET
|
BioPorto A/S
15. august 2024 Pressemeddelelse Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi København,...
BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024
August 15, 2024 02:37 ET
|
BioPorto A/S
August 15, 2024Announcement no. 18 BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 Continued strong growth in US sales...
BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
August 07, 2024 07:04 ET
|
BioPorto A/S
August 7, 2024News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, August 7, 2024 (GLOBE...
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
July 30, 2024 11:15 ET
|
BioPorto A/S
July 30, 2024 News Release BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms ADLM 2024 Conference –...
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
July 29, 2024 10:35 ET
|
BioPorto A/S
July 29, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 29, 2024 – BioPorto Diagnostics, a...
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
July 26, 2024 11:15 ET
|
BioPorto A/S
July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company...
Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker
July 17, 2024 11:50 ET
|
BioPorto A/S
July 17, 2024 News Release Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker COPENHAGEN, Denmark and BOSTON, MA, USA, July 17, 2024, (GLOBE...
Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury
July 11, 2024 11:15 ET
|
BioPorto A/S
July 11, 2024 News Release Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury COPENHAGEN, Denmark and...
Grant of Warrants
July 04, 2024 11:54 ET
|
BioPorto A/S
4 July 2024Announcement no. 17 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, July 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”)...
BioPorto confirms market acceptance of NGAL products with US standing order.
July 01, 2024 11:30 ET
|
BioPorto A/S
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) --...